StockNews.com Upgrades LeMaitre Vascular (NASDAQ:LMAT) to Buy

StockNews.com upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning.

Several other analysts have also commented on the company. Barrington Research lifted their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an outperform rating in a report on Friday, May 3rd. Roth Capital raised LeMaitre Vascular to a strong-buy rating in a report on Friday, May 31st. Stifel Nicolaus raised LeMaitre Vascular from a hold rating to a buy rating and lifted their price objective for the stock from $59.00 to $75.00 in a report on Friday, April 26th. Roth Mkm reaffirmed a buy rating and issued a $100.00 price objective on shares of LeMaitre Vascular in a report on Friday, May 31st. Finally, JMP Securities lifted their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the company a market outperform rating in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular has a consensus rating of Moderate Buy and an average target price of $77.57.

LeMaitre Vascular Trading Up 1.0 %

LeMaitre Vascular stock opened at $86.20 on Wednesday. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of 57.09, a PEG ratio of 2.60 and a beta of 0.89. The stock has a fifty day simple moving average of $80.92 and a two-hundred day simple moving average of $69.53. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $88.75.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, topping the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The company had revenue of $53.48 million during the quarter, compared to analyst estimates of $51.50 million. During the same quarter in the previous year, the company posted $0.27 earnings per share. LeMaitre Vascular’s revenue was up 13.6% compared to the same quarter last year. On average, equities research analysts forecast that LeMaitre Vascular will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 30th. Investors of record on Thursday, May 16th were given a dividend of $0.16 per share. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $0.64 annualized dividend and a yield of 0.74%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Insider Activity

In other news, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the transaction, the chief executive officer now directly owns 2,079,128 shares in the company, valued at $156,558,338.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the transaction, the chief executive officer now directly owns 2,079,128 shares in the company, valued at $156,558,338.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 68,906 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.70, for a total value of $5,216,184.20. Following the completion of the transaction, the chief executive officer now owns 2,133,428 shares in the company, valued at $161,500,499.60. The disclosure for this sale can be found here. Insiders have sold 127,437 shares of company stock worth $10,076,242 over the last ninety days. Corporate insiders own 10.79% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds have recently made changes to their positions in LMAT. YHB Investment Advisors Inc. purchased a new stake in shares of LeMaitre Vascular in the first quarter worth about $36,000. SRS Capital Advisors Inc. lifted its position in shares of LeMaitre Vascular by 325.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 524 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 199 shares in the last quarter. SG Americas Securities LLC bought a new stake in LeMaitre Vascular during the second quarter worth approximately $177,000. Finally, Envestnet Portfolio Solutions Inc. bought a new stake in LeMaitre Vascular during the first quarter worth approximately $206,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.